Alios Biopharma: Johnson & Johnson : J&J Posts Impairment Charge on Key Drug From Alios Deal

(marketscreener.com) By Colin Kellaher Johnson & Johnson (JNJ) on Tuesday said it recorded a $630 million impairment charge in the third quarter related to the key drug in its acquisition of Alios Biopharma Inc. and warned that it may post a further impairment on the asset. J&J in late 2014 agreed to pay $1.75 billion for Alios, an antiviral...http://www.marketscreener.com/JOHNSON-JOHNSON-4832/news/Johnson-Johnson-J-J-Posts-Impairment-Charge-on-Key-Drug-From-Alios-Deal-27431927/?utm_medium=RSS&utm_content=20181016